This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

OraSure Technologies' CEO Presents At Deutsche Bank AG Health Care Conference (Transcript)

OraSure Technologies, Inc. (OSUR)

Deutsche Bank AG Health Care Conference Call

May 7, 2012 8:40 am ET

Executives

Douglas A. Michels – President and Chief Executive Officer

Ronald H. Spair – Chief Operating Officer and Chief Financial Officer

Presentation

Unidentified Analyst

Good morning and welcome to the 37 th Annual DB Healthcare Conference. My name is [Robert Karofsky] and I’m with the MedTech team here at DB. Kicking things off this morning we have OraSure Technologies. With us we have CEO, Doug Michels; and CFO, Ron Spair.

Douglas A. Michels

Good morning, everybody, and special thanks to Deutsche Bank for inviting us to speak to you today and to attend this year’s conference. As Rob mentioned, Ron Spair is here with me. Ron is our Chief Financial Officer and Chief Operating Officer and given that today we’re going to be spending a shorter amount of time with the presentation and more time with questions, got to be a great opportunity to have Ron up here taking difficult questions that you might ask.

Before we begin, let me remind you that through this morning’s presentation, we will be talking about the futures forward-looking statements and obviously whenever you are talking about the future, there is uncertainty and so we ask you to refer to the company’s SEC filings 10-K and 10-Q for a more complete description of those factors that might impact future results.

I’m going to start out this morning like I usually do with just a couple of comments on the investment rationale for OraSure Technologies. As many of know, OraSure is an industry leader in the point-of-care, infectious disease and biological sample collection space. Our base products today address in excess of a $600 million global market and we are less than 20% penetrated. So we believe that with our traditional products, we still have quite a bit of room to continue growing this very fine business.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,254.74 +122.04 0.67%
S&P 500 2,111.56 +7.06 0.34%
NASDAQ 4,991.8640 +28.3370 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs